Page last updated: 2024-11-07

fpl 67047xx

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

FPL 67047XX: inhibits phospholipase A2; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID127885
CHEMBL ID434630
CHEMBL ID1234914
SCHEMBL ID5595498
MeSH IDM0228542

Synonyms (20)

Synonym
bdbm50040461
chembl434630
(s)-5-(4-benzyl-phenylsulfanyl)-4-((s)-7-phenyl-heptanoylamino)-pentanoic acid
(s)-5-(4-benzyl-phenylsulfanyl)-4-(7-phenyl-heptanoylamino)-pentanoic acid
CHEMBL1234914
4-(s)-[(1-oxo-7-phenylheptyl)amino]-5-[4-(phenylmethyl)phenylthio]pentanoic acid
1KVO ,
fpl 67047xx
154461-38-8
(s)-4-((1-oxo-7-phenylheptyl)amino)-5-((4-(phenylmethyl)phenyl)thio)pentanoic acid
fpl-67047xx
fpl67047xx
pentanoic acid, 4-((1-oxo-7-phenylheptyl)amino)-5-((4-(phenylmethyl)phenyl)thio)-, (s)-
BLFSPSZATDQQMK-NDEPHWFRSA-N
SCHEMBL5595498
(4s)-5-[(4-benzylphenyl)sulfanyl]-4-[(7-phenylheptanoyl)amino]pentanoic acid
Q27464066
DTXSID00934992
5-[(4-benzylphenyl)sulfanyl]-4-[(1-hydroxy-7-phenylheptylidene)amino]pentanoic acid
ar-c 67047mi
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Human Phospholipase A2Homo sapiens (human)IC50 (µMol)0.01300.01300.01300.0130AID977608
Phospholipase A2, membrane associatedHomo sapiens (human)IC50 (µMol)0.02100.00301.08118.0000AID158933
1-alkyl-2-acetylglycerophosphocholine esterase Sus scrofa (pig)IC50 (µMol)0.02250.01500.02250.0300AID159082; AID159084
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
phospholipid metabolic processPhospholipase A2, membrane associatedHomo sapiens (human)
inflammatory responsePhospholipase A2, membrane associatedHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPhospholipase A2, membrane associatedHomo sapiens (human)
lipid catabolic processPhospholipase A2, membrane associatedHomo sapiens (human)
killing of cells of another organismPhospholipase A2, membrane associatedHomo sapiens (human)
low-density lipoprotein particle remodelingPhospholipase A2, membrane associatedHomo sapiens (human)
intestinal stem cell homeostasisPhospholipase A2, membrane associatedHomo sapiens (human)
phosphatidylethanolamine metabolic processPhospholipase A2, membrane associatedHomo sapiens (human)
phosphatidylcholine metabolic processPhospholipase A2, membrane associatedHomo sapiens (human)
phosphatidic acid metabolic processPhospholipase A2, membrane associatedHomo sapiens (human)
arachidonic acid secretionPhospholipase A2, membrane associatedHomo sapiens (human)
positive regulation of inflammatory responsePhospholipase A2, membrane associatedHomo sapiens (human)
defense response to Gram-positive bacteriumPhospholipase A2, membrane associatedHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadePhospholipase A2, membrane associatedHomo sapiens (human)
regulation of neutrophil activationPhospholipase A2, membrane associatedHomo sapiens (human)
negative regulation of T cell proliferationPhospholipase A2, membrane associatedHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
phospholipase A2 activityPhospholipase A2, membrane associatedHomo sapiens (human)
phospholipid bindingPhospholipase A2, membrane associatedHomo sapiens (human)
calcium-dependent phospholipase A2 activityPhospholipase A2, membrane associatedHomo sapiens (human)
calcium ion bindingPhospholipase A2, membrane associatedHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
extracellular regionPhospholipase A2, membrane associatedHomo sapiens (human)
extracellular spacePhospholipase A2, membrane associatedHomo sapiens (human)
mitochondrial outer membranePhospholipase A2, membrane associatedHomo sapiens (human)
endoplasmic reticulumPhospholipase A2, membrane associatedHomo sapiens (human)
endoplasmic reticulum membranePhospholipase A2, membrane associatedHomo sapiens (human)
plasma membranePhospholipase A2, membrane associatedHomo sapiens (human)
secretory granulePhospholipase A2, membrane associatedHomo sapiens (human)
perinuclear region of cytoplasmPhospholipase A2, membrane associatedHomo sapiens (human)
extracellular exosomePhospholipase A2, membrane associatedHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID158792Concentration for hnps- Phospholipase A2 was evaluated using radioligand [3H]arachidonate binding assay in Escherichia coli membranes1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
High-resolution X-ray crystallography reveals precise binding interactions between human nonpancreatic secreted phospholipase A2 and a highly potent inhibitor (FPL67047XX).
AID159082Compound was tested for in vitro activity against porcine pancreatic phospholipase-A2 (PLA2) and micellar substrate with deoxycholate (DOC)1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Discovery of new non-phospholipid inhibitors of the secretory phospholipases A2.
AID158933Compound was tested for in vitro activity against S-phospholipase A2 (s-PLA2) isolated from human platelets1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Discovery of new non-phospholipid inhibitors of the secretory phospholipases A2.
AID1282017Inhibition of human sPLA2 expressed in Escherichia coli assessed as release of [14C]oleate2016Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7
Emerging targets and new small molecule therapies in Parkinson's disease treatment.
AID159084In vitro activity against porcine pancreatic phospholipase-A2 (PLA2) and monomerically dispersed substrate1994Journal of medicinal chemistry, Mar-04, Volume: 37, Issue:5
Discovery of new non-phospholipid inhibitors of the secretory phospholipases A2.
AID1811Experimentally measured binding affinity data derived from PDB1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
High-resolution X-ray crystallography reveals precise binding interactions between human nonpancreatic secreted phospholipase A2 and a highly potent inhibitor (FPL67047XX).
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
High-resolution X-ray crystallography reveals precise binding interactions between human nonpancreatic secreted phospholipase A2 and a highly potent inhibitor (FPL67047XX).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (50.00)18.2507
2000's0 (0.00)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.69 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (33.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (66.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]